Ataluren binds to multiple protein synthesis apparatus sites and competitively inhibits release factor-dependent termination

Shijie Huang; Arpan Bhattacharya; Mikel D. Ghelfi; Hong Li; Clark Fritsch; David M. Chenoweth; Yale E. Goldman; Barry S. Cooperman

doi:10.1038/s41467-022-30080-6

Nature Communications (May 2022)

Ataluren binds to multiple protein synthesis apparatus sites and competitively inhibits release factor-dependent termination

Shijie Huang,
Arpan Bhattacharya,
Mikel D. Ghelfi,
Hong Li,
Clark Fritsch,
David M. Chenoweth,
Yale E. Goldman,
Barry S. Cooperman

Affiliations

Shijie Huang: Department of Chemistry, University of Pennsylvania
Arpan Bhattacharya: Department of Chemistry, University of Pennsylvania
Mikel D. Ghelfi: Department of Chemistry, University of Pennsylvania
Hong Li: Department of Chemistry, University of Pennsylvania
Clark Fritsch: Department of Physiology, Perelman School of Medicine, University of Pennsylvania
David M. Chenoweth: Department of Chemistry, University of Pennsylvania
Yale E. Goldman: Department of Physiology, Perelman School of Medicine, University of Pennsylvania
Barry S. Cooperman: Department of Chemistry, University of Pennsylvania

DOI: https://doi.org/10.1038/s41467-022-30080-6
Journal volume & issue: Vol. 13, no. 1
pp. 1 – 14

Abstract

Read online

Ataluren is the only nonsense suppressor drug currently approved for clinical use. Here, the authors determine where ataluren binds to the ribosome and how it inhibits termination at nonsense codons.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal